272792-14-0

Basic information

• Product Name: methyl (4-cyanophenoxy)acetate
• Synonyms: methyl (4-cyanophenoxy)acetate;Methyl 2-(4-cyanophenoxy)acetate;2-(4-Cyanophenoxy)acetic acid methyl ester;A3604/0152744;methyl 2-(4-cyanophenoxy)ethanoate;ZINC01425998
• CAS NO: 272792-14-0
• Molecular Formula: C₁₀H₉NO₃
• Molecular Weight: 191.18336
• Mol File: 272792-14-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: methyl (4-cyanophenoxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (4-cyanophenoxy)acetate(272792-14-0)
• EPA Substance Registry System: methyl (4-cyanophenoxy)acetate(272792-14-0)

Safety Data

• Hazardous Substances Data: 272792-14-0(Hazardous Substances Data)

Usage

General Description

Methyl (4-cyanophenoxy)acetate is a chemical compound with the molecular formula C10H9NO3. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals due to its reactivity and versatility. methyl (4-cyanophenoxy)acetate is known for its ability to undergo various chemical reactions, making it a valuable building block in organic synthesis. It is also used in the production of fragrances, dyes, and other fine chemicals. Methyl (4-cyanophenoxy)acetate is a colorless liquid with a fruity odor and is considered to be slightly hazardous, requiring proper handling and storage to prevent exposure and potential harm.

Upstream product

• 1878-91-7 (4-bromophenoxy)acetic acid 
• 557-21-1 zinc(II) cyanide 
• 4841-23-0 (4-bromophenoxy)acetic acid methyl ester 
• 767-00-0 4-cyanophenol 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 521290-12-0 methyl 2-(4-(2H-tetrazol-5-yl)phenoxy)acetate 
• 132224-97-6 C₁₀H₁₃NO₃ 

Relevant articles and documents

Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists

GSK805 (1) is a potent RORγt inverse agonist, but a drawback of 1 is its low solubility, leading to a limited absorption in high doses. We have explored detailed structure-activity relationship on the amide linker, biaryl and arylsulfonyl moieties of 1 trying to improve solubility while maintaining RORγt activity. As a result, a novel series of carboxyl-containing biaryl urea derivatives was discovered as potent RORγt inverse agonists with improved drug-like properties. Compound 3i showed potent RORγt inhibitory activity and subtype selectivity with an IC50 of 63.8 nM in RORγ FRET assay and 85 nM in cell-based RORγ-GAL4 promotor reporter assay. Reasonable inhibitory activity of 3i was also achieved in mouse Th17 cell differentiation assay (76percent inhibition at 0.3 μM). Moreover, 3i had greatly improved aqueous solubility at pH 7.4 compared to 1, exhibited decent mouse PK profile and demonstrated some in vivo efficacy in an imiquimod-induced psoriasis mice model.

6-Aminoisoquinoline Compounds

6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.